ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Antares Pharma Reports on Their Study Using Testosterone Subcutaneous Injections
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 25015" data-attributes="member: 3"><p>Antares Pharma, Inc. announced that the journal Sexual Medicine has published the previously disclosed positive results from a multi-center, phase II clinical study evaluating the pharmacokinetic (PK) profile of testosterone enanthate administered once-weekly by subcutaneous injection using the VIBEX(R) QuickShot(R) auto injector in testosterone deficient men. The publication is entitled "Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study" authored by Jed Kaminetsky, MD et al. Dr. Kaminetsky is a urologist at University Urology Associates, Medical Director of Manhattan Medical Research and clinical assistant professor of urology at New York University School of Medicine. The study has been published in the October, 2015 issue of Sexual Medicine and can be located using the following link: <a href="http://onlinelibrary.wiley.com/doi/10.1002/sm2.80/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/sm2.80/full</a>.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 25015, member: 3"] Antares Pharma, Inc. announced that the journal Sexual Medicine has published the previously disclosed positive results from a multi-center, phase II clinical study evaluating the pharmacokinetic (PK) profile of testosterone enanthate administered once-weekly by subcutaneous injection using the VIBEX(R) QuickShot(R) auto injector in testosterone deficient men. The publication is entitled "Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study" authored by Jed Kaminetsky, MD et al. Dr. Kaminetsky is a urologist at University Urology Associates, Medical Director of Manhattan Medical Research and clinical assistant professor of urology at New York University School of Medicine. The study has been published in the October, 2015 issue of Sexual Medicine and can be located using the following link: [URL]http://onlinelibrary.wiley.com/doi/10.1002/sm2.80/full[/URL]. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Antares Pharma Reports on Their Study Using Testosterone Subcutaneous Injections
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top